Role of osteopontin in tumour progression

British Journal of Cancer

Volumn 90, Issue 10, 2004, Pages 1877-1881

  Rittling, S R ^a   Chambers, A F ^b  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Metastasis; Prognosis; Tumorigenesis; Tumour marker

Indexed keywords

BIOLOGICAL MARKER; OSTEOPONTIN; TUMOR MARKER; GLYCOPROTEIN; OSTEOPOIETIN;

ADVANCED CANCER; BIOLOGY; BLOOD; CANCER CONTROL; CARCINOGENESIS; CELL TRANSPLANTATION; COMPLEX FORMATION; DISEASE MARKER; GENETIC PROCEDURES; HUMAN; IN VITRO STUDY; INJECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY; TUMOR GROWTH; ANIMAL; CELL TRANSFORMATION; DISEASE COURSE; DISEASE MODEL; GENE EXPRESSION REGULATION; NEOPLASM; PATHOLOGY; REVIEW;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MICE; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 2942511574     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601839     Document Type: Short Survey

References (45)

1. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94: 513-521
2. Ariztia EV, Subbarao V, Solt DB, Rademaker AW, Iyer AP, Oltvai ZN (2003) Osteopontin contributes to hepatocyte growth factor-induced tumor growth and metastasis formation. Exp Cell Res 288: 257-267
3. Barraclough R, Chen HJ, Davies BR, Davies MP, Ke Y, Lloyd BH, Oates A, Rudland PS (1998) Use of DNA transfer in the induction of metastasis in experimental mammary systems. Biochem Soc Symp 63: 273-294
4. Bautista DS, Saad Z, Chambers AF, Tonkin KS, O'Malley F, Singhal H, Tokmakejian S, Bramwell V, Harris JF (1996) Quantification of osteopontin in human plasma with ELISA: basal levels in pre- and postmenopausal women. Clin Biochem 29: 231-239
5. Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF (1994) Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 54: 832-837
6. Bos JL (1989) ras Oncogenes in human cancer: a review. Cancer Res 49: 4682-4689
7. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR (1994) Osteopontin expression and distribution in human carcinomas. Am J Pathol 145: 610-623
8. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG (1996) Osteopontin expression in lung cancer. Lung Cancer 15: 311-323
9. Chang PL, Cao M, Hicks P (2003) Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells. Carcinogenesis 24: 1749-1758
10. Chen Y, Rittling SR (2003) Novel murine mammary epithelial cell lines that form osteolytic bone metastases: effect of strain background on tumor homing. Clin Exp Metast 20: 111-120
11. Clark GJ, Der CJ (1995) Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 35: 133-144
12. Coppola D, Szabo M, Boulware D, Schickor FK, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of OPN protein expression and pathologic stage across a wide variety of tumor histologies widespread detection of osteopontin protein expression in human tumors from different anatomical sites using the tissue array technique. Clin Cancer Res 10: 184-190
13. Crawford HC, Matrisian LM, Liaw L (1998) Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 58: 5206-5215
14. Das R, Mahabeleshwar GH, Kundu GC (2003) Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 278: 28593-28606
15. Denhardt DT, Giachelli C, Rittling SR (2001) Role of osteopontin in cellular signalling and toxicant injury. Annu Rev Pharmacol Toxicol 41: 723-749
16. Denhardt DT, Mistretta D, Chambers AF, Krishna S, Porter JF, Raghuram S, Rittling SR (2003) Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin Exp Metast 20: 77-84
17. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7: 4060-4066
18. Feng F, Rittling SR (2000) Mammary tumor development in MMTV-c-myc/ MMTV-v-Ha-ras transgenic mice is unaffected by osteopontin deficiency. Breast Cancer Res Treat 63: 71-79
19. Furger KA, Menon RK, Tuck AB, Bramwelll VH, Chambers AF (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1: 621-632
20. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF (2002) Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 95: 506-512
21. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549
22. Kim JH, Skates SJ, Uede T, Wong Kk KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287: 1671-1679
23. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9: 59-67
24. Leali D, Dell'Era P, Stabile H, Sennino B, Chambers AF, Naldini A, Sozzani S, Nico B, Ribatti D, Presta M (2003) Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol 171: 1085-1093
25. Medico E, Gentile A, Lo CC, Williams TA, Gambarotta G, Trusolino L, Comoglio PM (2001) Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res 61: 5861-5868
26. Nemoto H, Rittling SR, Yoshitake H, Furuya K, Amagasa T, Tsuji K, Nifuji A, Denhardt DT, Noda M (2001) Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res 16: 652-659
27. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC (2003) Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98: 119-127
28. Rittling SR, O'Regan A, Berman JS (2003) Osteopontin, a surprisingly flexible cytokine: functions revealed from knockout mice. In Contemporary Immunology: Cytokine Knockouts, Fantuzzi G (ed) pp 379-393. Totowa: Humana Press Inc.
29. Rudland PS, Platt-Higgins A, El Tanani M, De Silva RS, Barraclough R, Winstanley JH, Howitt R, West CR (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62: 3417-3427
30. 3 integrin-induced endothelial cell survival. J Cell Biol 141: 1083-1093
31. Senger DR, Perruzzi CA, Gracey CF, Papadopoulous A, Tenen DG (1988) Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res 48: 5770-5774
32. Senger DR, Wirth DF, Hynes RO (1979) Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16: 885-893
33. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, Harris JF (1997) Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3: 605-611
34. Sodek J, Ganss B, McKee MD (2000) Osteopontin. Crit Rev Oral Biol Med 11: 279-303
35. Tuck AB, Arsenault DM, O'Malley FP, Hota C, Ling MC, Wilson SM, Chambers AF (1999) Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18: 4237-4246
36. Tuck AB, Chambers AF (2001) The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 6: 419-429
37. Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF (2000) Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem 78: 465-475
38. Tuck AB, Hota C, Wilson SM, Chambers AF (2003) Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene 22: 1198-1205
39. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS, Chambers AF (1998) Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 79: 502-508
40. Tuck AB, O'Malley FP, Singhal H, Tonkin KS, Harris JF, Bautista D, Chambers AF (1997) Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 121: 578-584
41. Urquidi V, Sloan D, Kawai K, Agarwal D, Woodman AC, Tarin D, Goodison S (2002) Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin Cancer Res 8: 61-74
42. Wang-Rodriguez J, Urquidi V, Rivard A, Goodison S (2003) Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status. Breast Cancer Res 5: R136-R143
43. Wu Y, Denhardt DT, Rittling SR (2000) Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer 83: 156-163
44. Yamamoto N, Sakai F, Kon S, Morimoto J, Kimura C, Yamazaki H, Okazaki I, Seki N, Fujii T, Uede T (2003) Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J Clin Invest 112: 181-188
45. Zhu B, Suzuki K, Goldberg HA, Rittling SR, Denhardt DT, McCulloch CAG, Sodek J (2003) Osteopontin modulates CD444-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J Cell Physiol 198: 155-167